Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy.

Gedeborg, Rolf; Loeb, Stacy; Styrke, Johan; Kiiski-Berggren, Ritva; Garmo, Hans; Stattin, Pär

Gedeborg, Rolf; Loeb, Stacy; Styrke, Johan; Kiiski-Berggren, Ritva; Garmo, Hans; Stattin, Pär.

Afiliação

Gedeborg R; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Loeb S; Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York, USA.
Styrke J; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Kiiski-Berggren R; Department of Surgical and Perioperative Sciences, Anesthesiology and Intensive Care Medicine, Umeå University, Umeå, Sweden.
Garmo H; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Stattin P; Translational Oncology and Urology Research (TOUR), King's College London, Guy's Hospital, London, UK.

Int J Cancer ; 151(11): 1925-1934, 2022 Dec 01.

Article em En | MEDLINE | ID: mdl-35802468

Assuntos

COVID-19; Neoplasias da Próstata; Antagonistas de Androgênios/efeitos adversos; Androgênios; COVID-19/epidemiologia; Humanos; Masculino; Fatores de Risco; SARS-CoV-2

Palavras-chave

COVID-19; GnRH agonists; SARS-CoV-2; androgen deprivation therapy; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google